Recombinant Dna Technique Included In Method Of Making A Protein Or Polypeptide Patents (Class 435/69.1)
  • Patent number: 10689656
    Abstract: Methods and materials for genetically engineering methylotrophic yeast are provided.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: June 23, 2020
    Assignee: Impossible Foods Inc.
    Inventors: Smita Shankar, Martin Andrew Hoyt
  • Patent number: 10689662
    Abstract: Provided are isolated polynucleotides which comprise a nucleic acid sequence at least 80% identical to SEQ ID NO: 321, 1-320, 322-480, 793-2945 or 2946; isolated polypeptides which comprise an amino acid sequence at least 80% homologous to SEQ ID NO: 517, 481-516, 518-792, 2947-4662 or 4663, nucleic acid constructs comprising same, transgenic cells and plants expressing same and methods of using same for increasing yield, biomass, growth rate, vigor, oil content, fiber yield, fiber quality, abiotic stress tolerance, and/or nitrogen use efficiency of a plant.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: June 23, 2020
    Assignee: Evogene Ltd.
    Inventors: Eyal Emmanuel, Hagai Karchi
  • Patent number: 10682392
    Abstract: In some aspects, the invention teaches pharmaceutical compositions that include a TGF-beta ligand trap, and methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-beta ligand trap to reduce right ventricular systolic pressure in a subject.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: June 16, 2020
    Assignees: THE BRINGHAM AND WOMEN'S HOSPITAL, INC., ACCELERON PHARMA, INC.
    Inventors: Paul Yu, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves, Ravindra Kumar
  • Patent number: 10686681
    Abstract: A system used for identifying issues within a telecom network. Data is obtained from sources including probes and network elements. KPIs are identified for real-time streaming aggregation. Streaming data related to the KPIs is aggregated and an approximation of count-distinct subscribers and volume count is calculated, as well as count-distinct subscribers aggregating by each identified KPI. Drill objects found in the aggregated data are identified based on the calculations and real-time trending records are generated and stored for each drill object using an exponential moving average. Baseline averages are generated based on the real-time trending records. An increase in errors can then be detected based on the baseline averages and additionally aggregated real-time streaming data. Deviations in each drill object contributing to the detected increase in errors are then analyzed and a full case report is generated based on details of the deviations.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: June 16, 2020
    Assignee: ANRITSU COMPANY
    Inventors: Carlo Medas, Davide Motta
  • Patent number: 10683288
    Abstract: A compound having the structure:
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: June 16, 2020
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: James Leighton, Stephen Ho, Corinne Foley
  • Patent number: 10682388
    Abstract: The disclosure describes PELP1 binding peptides and peptoids and their use the interaction of PELP1 with molecules that lead to oncogenic signaling in cancers.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: June 16, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Ratna K. Vadlamudi, Monica Mann, Samaya Krishnan, Gangadhara Reddy Sareddy
  • Patent number: 10655133
    Abstract: Provided are: a method for preparing a DNA unit composition in which the mol number of a plurality of DNA units is more uniform, and a method for creating concatenated DNA. The method for preparing a DNA unit composition has: a step for preparing solutions which contain a plurality of DNA units to which an added sequence is linked, and preparing a solution for each type of DNA unit; and a step for, after preparing each of the solutions, measuring the concentration of the DNA unit in each of the solutions in a state where the added sequence is linked to the DNA unit, and on the basis of the results thereof, fractionating each of the solutions and making the mol number of the DNA unit in each of the solutions closer to being identical to one another.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: May 19, 2020
    Assignee: SYNPLOGEN CO., LTD.
    Inventors: Kenji Tsuge, Mitsuhiro Itaya
  • Patent number: 10655117
    Abstract: The present application relates to the field of enzyme engineering, especially relates to a pullulanase as well as preparation and use thereof. The pullulanase and coding gene thereof were obtained by random mutation by using the Error-prone PCR technique on the gene of wild-type pullulanase to obtain a mutant PLUM. The enzyme activity of the mutant PLUM was improved by 57.03% compared with the wild-type pullulanase PLUM.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: May 19, 2020
    Assignee: BEIJING HONGMING XINDA TECHNOLOGY CO., LTD.
    Inventors: Yu Wang, Litong Ban, Liang Huang, Ning Sun, Hongpeng Yang
  • Patent number: 10633640
    Abstract: The present disclosure relates to transaminase polypeptides capable of aminating a dicarbonyl substrate, and polynucleotides, vectors, host cells, and methods of making and using the transaminase polypeptides.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: April 28, 2020
    Assignee: Codexis, Inc.
    Inventors: Fabien Louis Cabirol, Haibin Chen, Anupam Gohel, Paulina Elena Salim, Derek J. Smith, Jacob Janey, Birgit Kosjek, Weng Lin Tang, Helen Hsieh, Son Q. Pham
  • Patent number: 10632182
    Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to methods for freeze-drying biological preparations, including peptides, antigens, antibodies, and especially, cells. Importantly, the disclosed methods preserve the viability, infectivity and immunogenicity of cells from the Apicomplexa phylum, the Sarcocystidae family, and in particular, cells from the Toxoplasma genus.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: April 28, 2020
    Inventors: Noel Yves Henri Jean Genin, Jean-Christophe Audonnet, Didier Roy, Edouard Seche, Patrick Gervais, Samira Khaldi-Plassart, Romain Useo, Joelle DeConinck
  • Patent number: 10624578
    Abstract: In embodiments, devices, methods and systems to analyze the different mediums of brain function in a mathematically uniform manner may be provided. These devices, methods and systems may manifest at several levels and ways relating to brain physiology, including neuronal activity, molecular chirality and frequency oscillations. For example, in an embodiment, a computer-implemented method for determining structure of living neural tissue may comprise receiving at least one signal from at least one read modality, the signal representing at least one physical condition of the living neural tissue, determining action potentials based on the signals received from the read modalities, determining frequency oscillations based on the signals received from the read modalities and the action potentials, and determining neuron network structures based on the signals received from the read modalities, the action potentials, and the frequency oscillations.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: April 21, 2020
    Inventor: Newton Howard
  • Patent number: 10617348
    Abstract: Embodiments of the present systems and methods may relate to a non-invasive system with diagnostic and treatment capacities that use a unified code that is intrinsic to physiological brain function. For example, in an embodiment, a computer-implemented method for affecting living neural tissue may comprise receiving at least one signal from at least one read modality, the signal representing release of photons from mitochondria of the living neural tissue, computing at least one signal to effect alterations to the living neural tissue based on the received input signal, the computed signal adapted to cause transmission of photons to the living neural tissue, and delivering the photons to the living neural tissue to effect alterations to the living tissue.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: April 14, 2020
    Inventor: Newton Howard
  • Patent number: 10619153
    Abstract: Materials and methods related to gene targeting (e.g., gene targeting with transcription activator-like effector nucleases; “TALENS”) are provided.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: April 14, 2020
    Assignees: Regents of the University of Minnesota, Iowa State University Research Foundation, Inc.
    Inventors: Daniel F. Voytas, Adam J. Bogdanove, Feng Zhang
  • Patent number: 10604750
    Abstract: The disclosure relates to acetyl-CoA carboxylase (ACC) variants and host cells expressing them for the production of malonyl-CoA derived compounds including fatty acid derivatives. Further contemplated are methods of producing increased amounts of malonyl-CoA derived compounds and related cell cultures.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: March 31, 2020
    Assignee: GENOMATICA, INC.
    Inventors: Derek L. Greenfield, Donald E. Trimbur, Andreas W. Schirmer, Cindy Chang, Behnaz Behrouzian, Jessica Winger
  • Patent number: 10605807
    Abstract: Methods and compositions for imaging and scanning Western or immunoblots are disclosed herewith.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: March 31, 2020
    Assignee: Bio-Rad Laboratories, Inc.
    Inventor: Clayton T. McKee
  • Patent number: 10590320
    Abstract: To provide novel adhesive molecules. An adhesive molecule having an amino acid sequence of SEQ ID NO. 1, or an amino acid sequence including a conservative substitution, a deletion, an insertion and/or a modification in the sequence of SEQ ID NO. 1.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: March 17, 2020
    Assignees: THE CHUGOKU ELECTRIC POWER CO., INC., SESSILE RESEARCH CORPORATION
    Inventors: Tsukasa Yoshizaki, Keiji Yamashita, Kyoko Kamiya, Kohichi Suzuki, Yoshio Hayashi
  • Patent number: 10590185
    Abstract: A genetically engineered live bacterium which is adapted to selectively replicate in and colonize a selected tissue type within the mammal, and concurrently produce within the selected tissue type at least one protease-sensitive cytotoxic molecule which is degradable by proteases within the selected tissue type, and at least one protease inhibitor peptide to inhibit the proteases within the selected tissue type from proteolytically degrading the protease sensitive cytotoxic molecule. The combination results in higher concentrations of the cytotoxic molecule local to the colonization, while permitting protease degradation of the cytotoxic molecule further away from the colonization.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: March 17, 2020
    Inventor: David Gordon Bermudes
  • Patent number: 10584157
    Abstract: Disclosed are peptides comprising amino acid residues of the dimer interface of human B7-1 and B7-2 and compositions and uses thereof.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: March 10, 2020
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD
    Inventors: Raymond Kaempfer, Revital Levy
  • Patent number: 10584351
    Abstract: This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immuunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: March 10, 2020
    Assignee: Intrexon Corporation
    Inventors: Jeremiah F. Roeth, Charles C. Reed, Brandon Cuthbertson, Sunil Chada, William E. Fogler
  • Patent number: 10584362
    Abstract: The present application provides a method for simultaneously synthesizing a biological flocculant with polysaccharide and ?-PGA as the active components by using Bacillus licheniformis. Bacillus licheniformis is inoculated to a slant culture medium to be cultured; a single colony on a fresh plate is inoculated to a seed culture medium to be cultured; and a seed fermentation broth is inoculated to a fermentation culture medium to be cultured, and then the biological flocculant having two different components is obtained. The flocculant synthesized in the present invention is high in activity and good in thermal stability; and especially, the flocculation effect of polysaccharide is relatively superior under acidic and neutral conditions, and the flocculation activity of ?-PGA is relatively higher under neutral and alkaline environments, which can satisfy a relatively large pH application range.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: March 10, 2020
    Assignee: Xiamen University
    Inventors: Ning He, Haosheng Yao, Yu Liu, Wencheng Yu, Shan Yan, Yuanpeng Wang, Qingbiao Li
  • Patent number: 10577614
    Abstract: The present invention relates to an optimized metabolic pathway design in P. pastoris. In particular, to a recombinant polycistronic expression construct for stable expression of multiple genes of interest in a yeast cell, preferably in P. pastoris.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: March 3, 2020
    Assignee: BISY GmbH
    Inventors: Martina Geier, Pia Fauland, Anton Glieder
  • Patent number: 10576127
    Abstract: An object of the present invention is the use of Irisin for the treatment and/or prevention of osteoporosis. In particular, the present invention refers to the use of recombinant irisin for the treatment and/or prevention of osteoporosis. A method for preventing and/or treating osteoporosis by administering an effective amount of irisin to a subject, is provided.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: March 3, 2020
    Assignees: UNIVERSITA' DEGLI STUDI DI BARI, UNIVERSITA' POLITECNICA DELLE MARCHE
    Inventors: Maria Grano, Graziana Colaianni, Concetta Cuscito, Giacomina Brunetti, Silvia Colucci, Saverio Cinti, Giorgio Mori
  • Patent number: 10570189
    Abstract: The present disclosure provides muteins of FVIII to which a biocompatible polymer may be attached to increase the circulatory half-life of the muteins, as well as conjugates of such muteins and biocompatible polymers.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: February 25, 2020
    Assignee: PFIZER INC.
    Inventors: James Apgar, Debra Pittman, Mark Stahl, Laura Lin, Justin Cohen
  • Patent number: 10568828
    Abstract: The present invention provides a peptide which shows a hair growth-promoting activity. The peptide of the present invention promotes the growth of follicular cells and increases the expression of a hair growth-related growth factor and hair growth-related factors, thereby showing an excellent effect in hair growth. The peptide of the present invention can be used for preventing and alleviating hair loss, promoting hair growth, and improving hair growth. In addition, the superior activity and stability of the peptide of the present invention allows the peptide to be very favorably applied to quasi drugs and cosmetics.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: February 25, 2020
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim, Eung-Ji Lee, Min Woong Kim
  • Patent number: 10570447
    Abstract: A method for synthesizing a nucleic acid includes synthesizing one or more nucleic acid fragments on a substrate. The synthesized one or more nucleic acid fragments may be amplified on the substrate. The method also includes sequencing the synthesized or amplified one or more nucleic acid fragments on the substrate. The sequencing may provide feedback to designs of the one or more nucleic acid fragments. The method further includes harvesting the synthesized or amplified one or more nucleic acid fragments based on sequencing. The synthesized or amplified one or more nucleic acid fragments may be assembled to generate a target nucleic acid.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: February 25, 2020
    Assignee: Illumina, Inc.
    Inventors: Mostafa Ronaghi, Molly He, Cheng-yao Chen, Michael Previte, M. Shane Bowen
  • Patent number: 10556946
    Abstract: Provided are novel human-derived anti-huntingtin (HTT) antibodies and biotechnological derivatives thereof, preferably capable of binding mutated and/or aggregated HTT species and or fragments thereof, as well as methods related thereto. The human-derived anti-HTT antibodies and biotechnological derivatives can be used in pharmaceutical and diagnostic compositions for HTT targeted immunotherapy of Huntington Disease and diagnosis thereof.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: February 11, 2020
    Assignee: Neurimmunie Holding AG
    Inventors: Marcel Maier, Jan Grimm
  • Patent number: 10548270
    Abstract: The present invention provides polynucleotides and related polypeptides of the protein GS. The invention provides genomic sequence for the GS gene. GS is responsible for controlling nitrogen utilization efficiency in plants. Glutamine synthase sequences are provided for improving grain yield and plant growth. The invention further provides recombinant expression cassettes, host cells and transgenic plants.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: February 4, 2020
    Assignee: PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: Rajeev Gupta, Kanwarpal Singh Dhugga
  • Patent number: 10543256
    Abstract: Physically and chemically stable pharmaceutical formulations in the form of an aqueous suspension comprising a reconstituted pulmonary surfactant are useful for the prophylaxis and/or treatment of respiratory distress syndrome (RDS) and other respiratory disorders.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: January 28, 2020
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Franco Sartor, Marisa Pertile, Annamaria Soliani Raschini
  • Patent number: 10545147
    Abstract: The invention is related to identification of an interferon-analog (IFNL4) protein and genetic association with spontaneous clearance of HCV infection and response to treatment for HCV infection.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: January 28, 2020
    Assignee: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Liudmila Prokunina, Thomas R. O'Brien, Brian Muchmore, Raymond P. Donnelly, Patricia A. Porter-Gill
  • Patent number: 10544426
    Abstract: Present invention relates to the use of the ALS inhibitor herbicides for controlling unwanted vegetation in ALS inhibitor herbicide tolerant Beta vulgaris plants, more especially, present invention relates to the use of ALS inhibitor herbicides for control of unwanted vegetation in Beta vulgaris, preferably in sugar beet growing areas in which the Beta vulgaris, preferably sugar beet comprise a mutation in codon 1705-1707 of an endogenous ALS gene encoding an ALS protein containing an amino acid that is different from tryptophan at position 569, preferably the tryptophan is substituted by leucine.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: January 28, 2020
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ruediger Hain, Gerhard Johann, Guenter Donn
  • Patent number: 10538552
    Abstract: The present invention refers to a method for binding a polycarboxylic acid to a solid phase. Further, the invention refers to a solid phase having a polycarboxylic acid immobilized thereto and methods of using the solid phase, e.g. for purifying His-tagged recombinant polypeptides.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: January 21, 2020
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Dirk Goerlich, Steffen Frey
  • Patent number: 10538799
    Abstract: Disclosed herein are vector systems for expression of polypeptides in eukaryotic cells; and methods of obtaining high-level expression of polypeptides in a eukaryotic cell. Methods and compositions for obtaining stable, long-term expression of recombinant polypeptides are also provided.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: January 21, 2020
    Assignee: Celltheon Corporation
    Inventor: Amita Goel
  • Patent number: 10537128
    Abstract: A yeast extract containing 0.2% or more of ?-Glu-Abu based on dry weight of the yeast extract is produced by culturing a yeast, such as Saccharomyces cervisiae or Candida utilis, in a medium containing a compound selected from Abu (L-2-aminobutyric acid) and ?-Glu-Abu (L-?-glutamyl-L-2-aminobutyric acid), and preparing a yeast extract from the obtained cells.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: January 21, 2020
    Assignee: AJINOMOTO CO., INC.
    Inventors: Hiroaki Nishiuchi, Misato Morita, Wataru Hoshino, Junko Yamazaki, Takayuki Ito, Kazuo Yamagishi
  • Patent number: 10526618
    Abstract: RNA guided Cas9 gene drives and method for their use are disclosed.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: January 7, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Kevin M. Esvelt, Andrea L. Smidler
  • Patent number: 10519250
    Abstract: The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: December 31, 2019
    Assignee: XOMA (US) LLC
    Inventors: Raphael D. Levy, Hassan Issafras, Agnes Choppin Holmes, Kirk W. Johnson, Amer M. Mirza, Daniel H. Bedinger, Rachel A. Hunt, Toshihiko Takeuchi, Kiranjit Kaur Ahluwalia, Robyn Cotter
  • Patent number: 10517926
    Abstract: Provided is an oligopeptide having preventive and therapeutic effects on infarction diseases. The oligopeptide contains a DE loop sequence of RANKL protein, and has inhibitory activity on proinflammatory cytokine secretion from cells.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: December 31, 2019
    Assignee: Osaka University
    Inventors: Munehisa Shimamura, Hironori Nakagami, Hitomi Kurinami, Ryuichi Morishita
  • Patent number: 10513697
    Abstract: A dissolved CO2 change in aqueous solutions affects directly the intracellular pH (pHi) value as it does so by influencing therefore important cellular processes. The enzyme carbonic anhydrase II (CAII) catalyzes the equilibrium of CO2 in aqueous solutions and because it alters the speed at which this equilibrium is reached it was identified as a strong candidate for metabolic engineering. The cell line stably expressing hCAII presented a better initial re-alkalinization of cytoplasm after induced CO2 acid load. The most alkaline pHi value associated to the lowest pHi variations was observed for that cell line in long term increased CO2 levels. In general, the increased CO2 profile triggered the quicker progress of G0G1-cell cycle phase for both transfected and control cell lines.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: December 24, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Betina Da Silva Ribeiro, Markus Emmler, Alexander Jockwer
  • Patent number: 10508147
    Abstract: The present invention relates to anti-Nodal antibodies and use of the anti-Nodal antibodies for diagnosing, preventing, and treating a Nodal-related disorder or disease.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: December 17, 2019
    Assignee: ANN & ROBERT H. LURIE CHILDREN'S HOSPITAL
    Inventors: Menotti Ruvo, Annamaria Sandomenico, Antonio Leonardi, Luca Sanguigno, Mary J. C. Hendrix, Elisabeth A. Seftor, Richard E. B. Seftor, Luigi Strizzi, Zhila Khalkhali-Ellis
  • Patent number: 10493137
    Abstract: An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s).
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: December 3, 2019
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Masaki Ishibashi, Fumiyoshi Okano
  • Patent number: 10493162
    Abstract: Methods and composition for cell-based therapy as well as somatostatin receptor-based therapy are described. For example, in certain aspects methods for administering an anti-tumor therapy using a signaling defective somatostatin receptor mutant are described. Furthermore, the invention provides compositions and methods involve a somatostatin constitutively active somatostatin receptor mutant.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: December 3, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventor: Vikas Kundra
  • Patent number: 10487113
    Abstract: A peptide having activity to improve skin condition is described. The peptide exhibits a very excellent effect in improving skin condition by inhibiting MMP2 activity. A composition containing the peptide exhibits excellent biological activities, such as inhibiting collagen decomposition and melanosome migration, and thus can be used in wrinkle reduction, skin regeneration, skin elasticity improvement, anti-skin aging, wound regeneration, acne reduction, skin regeneration or skin whitening. The composition containing the peptide can be used as a pharmaceutical composition for preventing or treating MMP activity-related diseases and inflammation diseases.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: November 26, 2019
    Assignee: Caregen Co., Ltd.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Patent number: 10488338
    Abstract: A method for visualizing and discriminating between DNA/RNA fragment(s) of unknown length(s) and an internal marker(s) of known length in a sample that is disposed in a common electrophoresis gel laneway. The method comprises labeling the DNA/RNA fragment(s) with a first dye and labeling the internal marker(s) with a second dye. The first and second dyes have discrete fluorescent emission spectra, which may be used to visually discriminate the DNA/RNA fragment(s) and the internal marker(s).
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: November 26, 2019
    Assignee: Coastal Genomics Inc.
    Inventors: Jared Slobodan, Matthew Nesbitt
  • Patent number: 10487136
    Abstract: The present disclosure relates to a method for the manufacture of recombinant antibody molecules comprising culturing a host cell sample transformed with an expression vector encoding a recombinant antibody molecule; adding an extraction buffer to the sample; and subjecting the sample to a heat treatment step; wherein the pH of the sample is detected after addition of the extraction buffer, and optionally adjusted, to ensure that the pH of the sample is 6 to 9 prior to the heat treatment step.
    Type: Grant
    Filed: February 2, 2011
    Date of Patent: November 26, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Jean-Pascal Pierre Bilgischer, Philip Jonathan Bassett, Mark Robert Pearce-Higgins, Andrew John Kenny
  • Patent number: 10485195
    Abstract: A sorghum seed comprising in its genome at least one polynucleotide encoding a polypeptide having an alanine to threonine substitution at position 93 of the sorghum AHAS protein large subunit. The plant has increased resistance to one or more herbicides, for example from the imidazolinone group, as compared to wild-type sorghum plants. The sorghum plant may comprise in its genome, one, two, three or more copies of a polynucleotide encoding a mutated large subunit of sorghum AHAS or a sorghum AHAS polypeptide of the invention. In this context, the sorghum plant may be tolerant to any herbicide capable of inhibiting AHAS enzyme activity. For example, the sorghum plant may be tolerant to herbicides of the imidazolinones type, such as imazethapyr, imazapir, and imazapic or to herbicides of the sulfonylurea group.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: November 26, 2019
    Assignee: Advanta International BV
    Inventors: Vicente Trucillo Uriarte, Andrés Daniel Zambelll, Marcos Kaspar, Pedro Alejandro Pardo
  • Patent number: 10485259
    Abstract: In some embodiments, the present disclosure relates to an avian-free egg white composition including 45-63% Ovalbumin, 9-15% Ovotransferrin, 0-15% Ovomucoid, 3-5% Ovoglobulin G2, 3-5% Ovoglobulin G3, 2.5-5% Ovomucin, 3-5% Lysozyme, 1-2% Ovoinhibitor, 0.8-1.5% Ovoglycoprotein, 0.6-1.0% Flavoprotein, 0.3-0.8% Ovomacroglobulin, 0.02-0.1% Avidin, and 0.02-0.1% Cystatin. In some embodiments, the composition includes an edible yeast and one or more of the preceding proteins. In some embodiments, the avian-free egg white further includes one or more of: flavor enhancers, calcium supplements, added vitamins, and a gelling agent. In some embodiments, the present disclosure pertains to a non-allergenic egg-white composition for human consumption. In some embodiments, the present disclosure pertains to methods of making the avian-free egg-white composition.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: November 26, 2019
    Inventor: Kedarnath Krishnamurthy Challakere
  • Patent number: 10485884
    Abstract: The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: November 26, 2019
    Inventors: Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Mustafa Diken, Daniel Fritz, Martin Meng, Lena Mareen Kranz, Kerstin Reuter
  • Patent number: 10480006
    Abstract: Compositions having pesticidal activity and methods for their use are provided. Compositions include isolated and recombinant polypeptides having pesticidal activity, recombinant and synthetic nucleic acid molecules encoding the polypeptides, DNA constructs and vectors comprising the nucleic acid molecules, host cells comprising the vectors, and antibodies to the polypeptides. Polynucleotide sequences encoding the polypeptides can be used in DNA constructs or expression cassettes for transformation and expression in organisms of interest. The compositions and methods provided are useful for producing organisms with enhanced pest resistance or tolerance. Transgenic plants and seeds comprising a nucleotide sequence that encodes a pesticidal protein of the invention are also provided. Such plants are resistant to insects and other pests. Methods are provided for producing the various polypeptides disclosed herein, and for using those polypeptides for controlling or killing a pest.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: November 19, 2019
    Assignee: AGBIOME, INC.
    Inventors: Jessica Parks, Kira Bulazel Roberts, Rebecca E. Thayer
  • Patent number: 10471119
    Abstract: A method of preventing or treating neurological disease includes administering to a subject in need thereof, a composition comprising an osmotin peptide selected from the group consisting of (a) an osmotin peptide having the amino acid sequence of SEQ ID NO: 1, and (b) an osmotin peptide having at least one amino acid residue substitution, deletion or insertion in the amino acid sequence of SEQ ID NO: 1. When a subject is treated with the osmotin peptide, nerve cells show no increase in growth rate, have little cytotoxicity, and suppress cell death, and when the osmotin peptide is administered to an animal model, the osmotin peptide infiltrated into the hippocampus of the brain and the hypothalamus of the brain, which is the deep part of the brain. Accordingly, the osmotin peptide is used as a composition for preventing, ameliorating, or treating neurological disease.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: November 12, 2019
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
    Inventor: Myeong Ok Kim
  • Patent number: 10465217
    Abstract: Disclosed is a microorganism of Escherichia sp. producing O-acetyl homoserine, and a method of producing O-acetyl homoserine in high yield using the microorganism.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: November 5, 2019
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Hyun Ah Kim, Ju Hee Seo, Yong Uk Shin, So Young Kim, Sang Kyoum Kim, Kwang Ho Na, Jee Yeon Bae, Sung Kwang Son, Hye Ryun Yoo, Jin Geun Choi
  • Patent number: 10456442
    Abstract: Methods for treating diabetes or obesity are provided comprising administering to the subject an amount of an agent that binds a central nervous system FGF receptor homodimer.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: October 29, 2019
    Assignee: Albert Einstein College of Medicine
    Inventor: Streamson Chua, Jr.